These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 13680141

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
    Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F.
    Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
    Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M.
    Osteoporos Int; 2006 Nov 30; 17(6):942-9. PubMed ID: 16550299
    [Abstract] [Full Text] [Related]

  • 9. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Ringe JD, Dorst A, Faber H, Ibach K, Preuss J.
    Rheumatology (Oxford); 2003 Jun 30; 42(6):743-9. PubMed ID: 12730532
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 30; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 12. Alendronate for the treatment of osteoporosis in men.
    Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A.
    N Engl J Med; 2000 Aug 31; 343(9):604-10. PubMed ID: 10979796
    [Abstract] [Full Text] [Related]

  • 13. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.
    Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW.
    Rheumatol Int; 2004 Mar 31; 24(2):63-70. PubMed ID: 14513268
    [Abstract] [Full Text] [Related]

  • 14. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Ortolani S.
    Osteoporos Int; 1993 Mar 31; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE).
    J Bone Miner Res; 2004 Aug 31; 19(8):1241-9. PubMed ID: 15231010
    [Abstract] [Full Text] [Related]

  • 18. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD, Faber H, Fahramand P, Schacht E.
    J Rheumatol Suppl; 2005 Sep 31; 76():33-40. PubMed ID: 16142849
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M, Bultink IE, Dijkmans BA, Lems WF.
    Osteoporos Int; 2005 Nov 31; 16(11):1432-5. PubMed ID: 15883662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.